This site is intended for health professionals only

Bevacizumab for breast cancer

teaser

Article continues below this sponsored advert
Featured Image
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
Advertisement

Bevacizumab (Avastin®) has been launched in the UK for first-linetreatment of metastatic breast cancer in combination with paclitaxel.The drug is already licensed for treating metastatic bowel cancer.Approval was based on a phase III trial in 722 women with locallyrecurrent or metastatic breast cancer, randomised to receive treatmentwith paclitaxel with or without bevacizumab. According to manufacturerRoche, patients on the combination had a median progression-freesurvival of 13.3 months vs 6.7 months in the paclitaxel group. Thecompany will submit overall survival data analysis to EU regulatoryauthorities during 2007.

New Electronic Library for Medicines 10/5/2007






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x